Highlights the need for careful monitoring and optimization of cardiovascular drug therapy in the elderly due to age-related pharmacokinetic and pharmacodynamic changes.
May support cautious CV drug use in elderly; leaves open optimal regimens pending dedicated trials.
Pharmacologic treatment of cardiovascular disease is both challenging and rewarding. Multiple medications and the variable nature of most cardiac problems necessitate careful monitoring of drug regimens in patients of any age. The elderly require even more attention to optimize therapy in light of variable drug absorption, effects, metabolism, and excretion. This challenge will present itself more frequently as the US population ages.
No takes yet. Share an insight, caveat, or question.
Baldwin et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: